Xingqi eye medicine: SQ-129 vitreous slow-release injection is used in the first case of clinical trial of diabetic macular edema stage I/II.

Xingqi Eye Medicine announced that the company's research and development of SQ-129 intravitreal sustained-release injection was completed today with the first subject enrolled in the "Phase I/II clinical trial of the safety, pharmacokinetic characteristics and preliminary efficacy of SQ-129 intravitreal sustained-release injection for the treatment of diabetic macular edema", officially entering the Phase I/II clinical trial.